Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:AGN
- CUSIP: 01849010
- Web: www.allergan.com
Capitalization:- Market Cap: $68.42 billion
- Outstanding Shares: 334,306,000
Average Prices:- 50 Day Moving Avg: $229.79
- 200 Day Moving Avg: $236.07
- 52 Week Range: $184.50 - $256.80
P/E:- Trailing P/E Ratio: 6.24
- Foreward P/E Ratio: 11.49
- P/E Growth: 0.96
Sales & Book Value:- Annual Revenue: $15.07 billion
- Price / Sales: 4.54
- Book Value: $210.39 per share
- Price / Book: 0.97
Dividend:- Annual Dividend: $2.80
- Dividend Yield: 1.4%
Profitability:- EBIDTA: $6.15 billion
- Net Margins: 79.17%
- Return on Equity: 7.37%
- Return on Assets: 4.17%
Debt:- Debt-to-Equity Ratio: 0.38%
- Current Ratio: 1.21%
- Quick Ratio: 1.10%
Misc:- Average Volume: 2.05 million shs.
- Beta: 1.18
- Short Ratio: 3.43
Frequently Asked Questions for Allergan PLC. (NYSE:AGN)
What is Allergan PLC.'s stock symbol?
Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?
Allergan PLC. declared a quarterly dividend on Wednesday, August 2nd. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share on Friday, September 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Wednesday, August 16th. View Allergan PLC.'s Dividend History.
How were Allergan PLC.'s earnings last quarter?
Allergan PLC. (NYSE:AGN) announced its earnings results on Thursday, August, 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks' consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.'s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. View Allergan PLC.'s Earnings History.
When will Allergan PLC. make its next earnings announcement?
What guidance has Allergan PLC. issued on next quarter's earnings?
Allergan PLC. updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $16.05-16.45 for the period, compared to the Thomson Reuters consensus estimate of $16.08. The company issued revenue guidance of $15.85-16.05 billion, compared to the consensus revenue estimate of $15.81 billion.
Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?
18 brokers have issued 1-year price objectives for Allergan PLC.'s stock. Their forecasts range from $228.00 to $400.00. On average, they anticipate Allergan PLC.'s stock price to reach $275.24 in the next year. View Analyst Ratings for Allergan PLC..
What are analysts saying about Allergan PLC. stock?
Here are some recent quotes from research analysts about Allergan PLC. stock:
- 1. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
- 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (7/11/2017)
- 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
Who are some of Allergan PLC.'s key competitors?
Some companies that are related to Allergan PLC. include Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), Gilead Sciences (GILD), Medtronic PLC (MDT), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), Thermo Fisher Scientific (TMO), Biogen (BIIB), Aetna (AET), Anthem (ANTM), Shire PLC (SHPG), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TKPYY).
Who owns Allergan PLC. stock?
Allergan PLC.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.80%), State Street Corp (4.66%), Northern Trust Corp (1.34%), Bank of New York Mellon Corp (1.03%), TIAA CREF Investment Management LLC (0.90%) and Paulson & CO. Inc. (0.81%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..
Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?
Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Farallon Capital Management LLC, State Street Corp, American Century Companies Inc., Renaissance Technologies LLC, Paulson & CO. Inc., Epoch Investment Partners Inc. and Bank of New York Mellon Corp. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..
Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?
Allergan PLC.'s stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, Eaton Vance Management, Harbour Capital Advisors LLC, Balyasny Asset Management LLC, HealthCor Management L.P., Iridian Asset Management LLC CT and CI Investments Inc.. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders and Maria Teresa Hilado. View Insider Buying and Selling for Allergan PLC..
How do I buy Allergan PLC. stock?
Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan PLC.'s stock price today?
One share of Allergan PLC. stock can currently be purchased for approximately $204.65.
MarketBeat Community Rating for Allergan PLC. (NYSE AGN)MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 12 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $275.24 (34.49% upside) |
Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/23/2017 | Cowen and Company | Reiterated Rating | Outperform | $400.00 | N/A |  |
| 9/22/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $231.00 | Low | |
| 9/20/2017 | Citigroup Inc. | Reiterated Rating | Buy | $280.00 | Low | |
| 9/20/2017 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | $284.00 -> $228.00 | Medium | |
| 9/12/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $262.00 | Low | |
| 9/11/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | | Low | |
| 9/6/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $285.00 | Medium | |
| 8/14/2017 | Argus | Reiterated Rating | Buy | $280.00 | Low | |
| 8/5/2017 | Credit Suisse Group | Set Price Target | Buy | $286.00 -> $288.00 | Low | |
| 8/2/2017 | Mizuho | Reiterated Rating | Buy | $267.00 | Low | |
| 7/14/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $231.00 | Low | |
| 5/25/2017 | Sanford C. Bernstein | Reiterated Rating | Outperform | | Low | |
| 5/10/2017 | Goldman Sachs Group, Inc. (The) | Downgrade | Buy -> Neutral | $262.00 | High | |
| 2/9/2017 | Leerink Swann | Boost Price Target | Buy | $280.00 | N/A | |
| 12/23/2016 | Bank of America Corporation | Reiterated Rating | Buy | $280.00 | N/A | |
| 12/5/2016 | J P Morgan Chase & Co | Set Price Target | Buy | $300.00 | N/A | |
| 11/21/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 10/31/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $250.00 | N/A | |
| 4/18/2016 | Guggenheim | Initiated Coverage | Neutral | | N/A | |
| 4/12/2016 | S&P Equity Research | Reiterated Rating | Buy | | N/A | |
| 4/7/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $317.00 -> $275.00 | N/A | |
| 4/7/2016 | Canaccord Genuity | Reiterated Rating | Buy | | N/A | |
| 4/7/2016 | Susquehanna Bancshares Inc | Downgrade | Positive -> Neutral | $345.00 -> $275.00 | N/A | |
| 4/5/2016 | Nomura | Reiterated Rating | Buy | $350.00 -> $330.00 | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Allergan PLC. (NYSE:AGN)Earnings History by Quarter for Allergan PLC. (NYSE AGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $4.19 | | | | | N/A | |
| 8/3/2017 | Q2 2017 | $3.95 | $4.02 | $3.95 billion | $4.01 billion | View | Listen | |
| 5/9/2017 | Q1 2017 | $3.32 | $3.35 | $3.53 billion | $3.57 billion | View | Listen | |
| 2/8/2017 | Q416 | $3.76 | $3.90 | $3.77 billion | $3.86 billion | View | Listen | |
| 11/2/2016 | Q316 | $3.57 | $3.32 | $3.73 billion | $3.62 billion | View | Listen | |
| 8/8/2016 | Q216 | $3.34 | $3.35 | $4.10 billion | $3.68 billion | View | Listen | |
| 5/10/2016 | Q116 | $3.03 | $3.04 | $3.97 billion | $3.80 billion | View | Listen | |
| 2/22/2016 | Q415 | $3.36 | $3.41 | $4.20 billion | $4.20 billion | View | Listen | |
| 11/4/2015 | Q315 | $3.20 | $3.48 | $5.71 billion | $4.10 billion | View | N/A | |
| 8/6/2015 | Q215 | $4.41 | $4.41 | $5.71 billion | $5.76 billion | View | N/A | |
| 11/5/2014 | Q414 | $1.83 | $2.17 | $1.90 billion | $1.91 billion | View | N/A | |
| 8/5/2014 | Q314 | $1.76 | $1.78 | $1.78 billion | $1.79 billion | View | Listen | |
| 7/21/2014 | Q214 | $1.44 | $1.51 | $1.77 billion | $1.83 billion | View | N/A | |
| 4/30/2014 | Q114 | $1.13 | $1.18 | $1.60 billion | $1.65 billion | View | N/A | |
| 2/4/2014 | Q413 | $1.34 | $1.12 | $1.65 million | $1.66 million | View | N/A | |
| 10/29/2013 | Q313 | $1.20 | $1.23 | $1.53 billion | $1.23 billion | View | Listen | |
| 7/31/2013 | Q2 2013 | $1.20 | $1.22 | $1.56 billion | $1.60 billion | View | N/A | |
| 5/1/2013 | Q1 2013 | $0.96 | $0.98 | $1.44 billion | $1.46 billion | View | N/A | |
| 2/5/2013 | Q4 2012 | $1.20 | $1.15 | $1.51 million | $1.48 million | View | N/A | |
| 10/30/2012 | Q312 | $1.04 | $1.06 | $1.43 billion | $1.39 billion | View | N/A | |
| 8/1/2012 | | $1.06 | $1.07 | | | View | N/A | |
| 5/2/2012 | | $0.87 | $0.86 | | | View | N/A | |
| 2/2/2012 | | $1.00 | $1.00 | | | View | N/A | |
| 10/26/2011 | | $0.90 | $0.92 | | | View | N/A | |
| 8/3/2011 | | $0.95 | $0.96 | | | View | N/A | |
| 5/4/2011 | | $0.74 | $0.77 | | | View | N/A | |
| 2/2/2011 | | $0.89 | $0.88 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Allergan PLC. (NYSE:AGN)2017 EPS Consensus Estimate: $16.25
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $3.33 | $3.55 | $3.44 |
| Q2 2017 | 2 | $4.00 | $4.07 | $4.04 |
| Q3 2017 | 3 | $4.09 | $4.16 | $4.14 |
| Q4 2017 | 3 | $4.52 | $4.72 | $4.64 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Allergan PLC. (NYSE:AGN)| Most Recent Dividend: | 9/15/2017 |
| Annual Dividend: | $2.80 |
| Dividend Yield: | 1.37% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 9.95% (Trailing 12 Months of Earnings)
17.22% (Based on This Year's Estimates)
15.72% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Allergan PLC. (NYSE AGN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/2/2017 | Quarterly | $0.70 | 1.12% | 8/16/2017 | 8/18/2017 | 9/15/2017 |
| 5/5/2017 | quarterly | $0.70 | 0.01% | 5/16/2017 | 5/18/2017 | 6/15/2017 |
| 11/2/2016 | quarterly | $0.70 | | 2/24/2017 | 2/28/2017 | 3/28/2017 |
| 2/4/2015 | quarterly | $0.05 | 0.09% | 2/5/2015 | 2/9/2015 | 3/20/2015 |
| 10/27/2014 | quarterly | $0.05 | | | 11/20/2014 | 12/11/2014 |
| 7/28/2014 | quarterly | $0.05 | 0.12% | 8/13/2014 | 8/15/2014 | 9/5/2014 |
| 5/7/2014 | quarterly | $0.05 | 0.12% | 5/21/2014 | 5/23/2014 | 6/13/2014 |
| 2/5/2014 | quarterly | $0.05 | 0.17% | 2/26/2014 | 2/28/2014 | 3/21/2014 |
| 10/30/2013 | quarterly | $0.05 | 0.22% | 11/18/2013 | 11/20/2013 | 12/11/2013 |
| 7/31/2013 | quarterly | $0.05 | 0.22% | 8/20/2013 | 8/22/2013 | 9/12/2013 |
| 5/2/2013 | quarterly | $0.05 | 0.2% | 5/21/2013 | 5/23/2013 | 6/13/2013 |
| 2/6/2013 | quarterly | $0.05 | 0.18% | 2/26/2013 | 2/28/2013 | 3/21/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 82.02%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/18/2017 | Nesli Basgoz | Director | Sell | 1,889 | $220.45 | $416,430.05 | |
| 3/2/2017 | Paul Bisaro | Director | Sell | 70,000 | $246.68 | $17,267,600.00 | |
| 12/8/2016 | Nesli Basgoz | Director | Sell | 500 | $188.72 | $94,360.00 | |
| 11/21/2016 | Brent L. Saunders | CEO | Buy | 5,250 | $189.13 | $992,932.50 | |
| 11/11/2016 | Maria Teresa Hilado | CFO | Buy | 1,422 | $210.64 | $299,530.08 | |
| 6/2/2016 | Maria Teresa Hilado | CFO | Buy | 661 | $241.57 | $159,677.77 | |
| 5/11/2016 | Nesli Basgoz | Director | Sell | 459 | $225.10 | $103,320.90 | |
| 12/7/2015 | Nesli Basgoz | Director | Sell | 2,300 | $312.96 | $719,808.00 | |
| 8/24/2015 | Paul Bisaro | Chairman | Buy | 1,000 | $297.42 | $297,420.00 | |
| 8/21/2015 | Brent L Saunders | CEO | Buy | 1,000 | $301.94 | $301,940.00 | |
| 4/22/2014 | Scott Sherman | EVP | Sell | 14,500 | $155.82 | $2,259,390.00 | |
| 2/21/2014 | Louis Lavigne, Jr. | Director | Sell | 5,400 | $125.79 | $679,266.00 | |
| 2/19/2014 | Dawn Hudson | Director | Sell | 4,200 | $126.35 | $530,670.00 | |
| 2/19/2014 | Jeffrey Edwards | CFO | Sell | 38,900 | $126.39 | $4,916,571.00 | |
| 2/19/2014 | Raymond Diradoorian | EVP | Sell | 23,000 | $126.66 | $2,913,180.00 | |
| 2/18/2014 | Scott Sherman | EVP | Sell | 5,001 | $125.74 | $628,825.74 | |
| 1/14/2014 | Scott Whitcup | VP | Sell | 42,000 | $117.80 | $4,947,600.00 | |
| 12/27/2013 | Julian Gangolli | VP | Sell | 52,500 | $110.05 | $5,777,625.00 | |
| 12/20/2013 | Scott Whitcup | VP | Sell | 33,000 | $108.80 | $3,590,400.00 | |
| 10/15/2013 | Trevor Jones | Director | Sell | 2,000 | $90.14 | $180,280.00 | |
| 9/16/2013 | Trevor Jones | Director | Sell | 2,000 | $89.78 | $179,560.00 | |
| 8/15/2013 | Trevor Jones | Director | Sell | 2,000 | $89.89 | $179,780.00 | |
| 8/6/2013 | Jeffrey Edwards | CFO | Sell | 69,200 | $91.17 | $6,308,964.00 | |
| 7/15/2013 | Trevor M Jones | Director | Sell | 2,000 | $91.15 | $182,300.00 | |
| 6/17/2013 | Trevor M Jones | Director | Sell | 2,000 | $101.25 | $202,500.00 | |
| 5/15/2013 | Trevor M Jones | Director | Sell | 2,000 | $103.40 | $206,800.00 | |
| 5/9/2013 | Jeffrey L Edwards | CFO | Sell | 84,000 | $103.49 | $8,693,160.00 | |
| 11/26/2012 | Trevor M Jones | Director | Sell | 2,500 | $91.30 | $228,250.00 | |
| 10/5/2012 | David E I Pyott | CEO | Sell | 616,300 | $93.73 | $57,765,799.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
| Source: |
|
Allergan PLC. (AGN) Chart for Saturday, September, 23, 2017
